- Conditions
- Cardiomyopathy, Hypertrophic Obstructive
- Interventions
- BHB-1893, Metoprolol
- Drug
- Lead sponsor
- Braveheart Bio, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Manhasset, New York • Rock Hill, South Carolina • Plano, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–344
of 344
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Coronary Artery Disease, Aortic Valve Disorder, Heart Failure, Aortic Valve Stenosis, Aortic Valve Insufficiency
- Interventions
- Implantation of CEP Magna Ease Model 3300TFX
- Device
- Lead sponsor
- Edwards Lifesciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 283 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2018
- U.S. locations
- 5
- States / cities
- Sacramento, California • Camden, New Jersey • Morristown, New Jersey + 2 more
- Conditions
- Aortic Stenosis
- Interventions
- Physician Notification Letter
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 940 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Aortic Stenosis
- Interventions
- Pelacarsen (TQJ230) 80mg, Matching placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 502 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 35
- States / cities
- Huntsville, Alabama • Beverly Hills, California • Covina, California + 26 more
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- High intensity exercise, Moderate intensity exercise
- Behavioral
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Non-obstructive Hypertrophic Cardiomyopathy
- Interventions
- Ninerafaxstat 200mg MR, Placebo
- Drug
- Lead sponsor
- Imbria Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 22
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 18 more
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- Ranolazine
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Obstructive Hypertrophic Cardiomyopathy
- Interventions
- Mavacamten, Non-mavacamten symptomatic oHCM therapy
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 60
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 48 more